| Barchart Demo Center |
$2,17
-0,02 (-0,91%)
en date du mai 31, 2024
en date du mai 31, 2024
| Dernière | 2,17 |
|---|---|
| Variation | -0,02 (-0,91%) |
| Ouverture | 2,17 |
| Clôture précédente | 2,19 |
| Écart (actuel) |
2,11
2,29
|
| Écart 52 semaines |
0,53
3,03
|
| Volume | 293 100 |
| Volume Moyen | 508 955 |
| Secteur | SIC-2836 Biological Products, (No Disgnostic Substanc |
Perfomance Comparison
| Nom | Aujourd'hui | 3-mois | 1 an |
|---|---|---|---|
| CGEN |
 -0,91% |
 -19,33% |
 +104,72% |
| DJIA |
 +1,51% |
-2,09% |
+16,90% |
| S&P 500 |
+0,80% |
+1,01% |
+25,49% |
Statistiques clef
| BPA Annuel | -0,19 |
|---|---|
| Rendement dividendes | 0,00% |
| Rapport Prix/Bénéfices | N/A |
| Market Capitalization, $K | 189 710 |
| Alpha pondéré | +20,05 |
| Écart-type | -0,12 |
| Marge d'exploitation | N/A |
| Beta | 2,72 |
Taux de croissance
| Cette année | +9,60% | |||
| 1 An(s) | +106,67% | |||
| 3 An(s) | -69,99% | |||
| 5 An(s) | -32,40% | |||
| 10 An(s) | -73,21% |
Opinion
| Vendre | Conserver | Acheter |
Articles récents
Compugen Reports First Quarter 2024 Results
PR Newswire - Mon May 20, 06:00AM CDT
Enrollment completed and on track to present data from COM701 + COM902 + pembrolizumab platinum resistant ovarian cancer study in Q4 2024 Data from COM701 +...(version intégrale)
CGEN: 2,17 (-0,02)
Compugen Appoints David Silberman as Chief Financial
PR Newswire - Wed May 15, 06:00AM CDT
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...(version intégrale)
CGEN: 2,17 (-0,02)
Compugen to Release First Quarter 2024 Results on
PR Newswire - Mon May 06, 06:00AM CDT
/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...(version intégrale)
CGEN: 2,17 (-0,02)
Compugen to Present New Clinical Data Showing COM701
PR Newswire - Thu Apr 25, 06:00AM CDT
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...(version intégrale)
CGEN: 2,17 (-0,02)
Compugen Publishes Paper in Cancer Immunology Research
PR Newswire - Wed Apr 10, 06:00AM CDT
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...(version intégrale)
CGEN: 2,17 (-0,02)